ABSTRACT
Introducción. La kinesiología respiratoria cuenta con una amplia variedad de estrategias terapéuticas para el tratamiento de pacientes con disfunción respiratoria, entre las cuales se pueden mencionar las técnicas instrumentales. En la actualidad, existe una amplia variedad de ellas, la gran mayoría frecuentemente utilizadas en la práctica clínica. No obstante, la literatura que respalda su uso es heterogénea al igual que sus protocolos de aplicación. El objetivo de esta revisión es describir las técnicas kinesiológicas instrumentales más utilizadas en la práctica clínica teniendo como base una propuesta de clasificación. Se incluyen los siguientes dispositivos: Threshold PEP, Mascarilla PiPEP, TheraPEP, Flutter, Acapella, RC-Cornet, chaleco oscilatorio/compresivo torácico de alta frecuencia, ventilación percusiva intrapulmonar e incentivador volumétrico y flujométrico. Estas se describen de acuerdo a sus características principales, principios fisiológicos, protocolos de aplicación y evidencia disponible en la literatura.
Background. Respiratory physiotherapy has various therapeutic strategies for treating patients with respiratory dysfunction, including mechanical devices. Currently, a wide variety of these devices exist, and many are frequently used in clinical practice. However, the literature supporting their use is heterogeneous, as well as their application protocols. This paper aims to provide an overview of the most used devices in respiratory physiotherapy at clinical practice based on a proposed classification. The following devices were included: Threshold PEP, PiPEP mask, TheraPEP, Flutter, Acapella, RC-Cornet, High frequency chest wall compression/oscillation, Intrapulmonary Percussive Ventilation, flow and volume spirometer. They were described according to their main characteristics, physiological mechanisms, application protocols and evidence from literature.
ABSTRACT
INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) is currently one of the most common liver diseases worldwide. Recent data suggest that loss of skeletal muscle mass and function (i.e. sarcopenia) is highly prevalent and frequently overlooked in NAFLD patients. Experimental and clinical data suggest that the relationship between NAFLD and sarcopenia is pathophysiologically complex and bi-directional and there is a growing interest in unveiling how sarcopenia could influence NAFLD development and progression. AREAS COVERED: PubMed/MEDLINE was searched for articles related to concomitant occurrence of NAFLD and sarcopenia between January 2013 and April 2020. Areas covered in this review include: (1) updated sarcopenia diagnosis strategy, (2) discussion of current data on pathophysiological connections between NAFLD and sarcopenia, and (3) analysis of current and future therapeutic implications of this knowledge. EXPERT OPINION: Clinical studies describe a consistent association between NAFLD and sarcopenia, although a cause-effect relation remains to be determined. Active implementation of current diagnosis algorithms and optimized treatment can prevent sarcopenia related complications in subjects with NAFLD. Pathogenic pathways implicated in this relation are multiple and complex, a better understanding of them can provide novel biomarkers and targeted therapies that will hopefully have an important impact in NAFLD management.
